This clinical heterogeneity demonstrates the current inability to predict cancer aggressiveness with certainty at diagnosis, along with the failure of serum prostate‐specific antigen (PSA) and imaging to detect cancer spread beyond the prostate until the disease is advanced [1]. This evidence concerns the gene KLK3 and cancer.